Does Molina Healthcare cover GLP-1 medications?
medicaid
Molina focuses on Medicaid managed care and marketplace plans, ~5 million members across 18+ states.
Molina coverage by drug
- Limited coverageWegovysemaglutide
Each state decides. KFF counted 13 state Medicaid programs covering GLP-1s for obesity in January 2026, and Massachusetts ended coverage in July 2026. Check your state's preferred drug list.
- Limited coverageZepboundtirzepatide
Zepbound follows your state's Medicaid rules for weight-loss drugs. Check your state's preferred drug list.
- Covered (prior auth required)Ozempicsemaglutide
State Medicaid programs cover Ozempic for type 2 diabetes, typically with prior authorization. Check your state's preferred drug list.
- Covered (prior auth required)Mounjarotirzepatide
State Medicaid programs cover Mounjaro for type 2 diabetes, typically with prior authorization. Check your state's preferred drug list.
- Limited coverageSaxendaliraglutide
Saxenda follows your state's Medicaid rules for weight-loss drugs. Check your state's preferred drug list.
- CoveredZoloftsertraline
State Medicaid programs cover generic sertraline. Check your state's preferred drug list.
- CoveredLexaproescitalopram
State Medicaid programs cover generic escitalopram. Check your state's preferred drug list.
- Varies by planViagrasildenafil
Federal law lets states exclude drugs used for erectile dysfunction unless used for another FDA-approved condition (42 U.S.C. 1396r-8(d)(2)(H)).
- Varies by planCialistadalafil
States may exclude tadalafil for erectile dysfunction; its FDA-approved use for benign prostatic hyperplasia is outside that exclusion.
- Limited coveragePropeciafinasteride
Federal law lets states exclude drugs used for hair growth (42 U.S.C. 1396r-8(d)(2)(C)); finasteride 5 mg for BPH is a different use.
Reminder: coverage varies by plan
Molina Healthcare offers many plan designs. The same medication can be covered under one Molina plan and excluded from another. Always confirm with your specific plan's formulary or call the number on your insurance card before assuming coverage.
Frequently asked
Does Molina Healthcare cover GLP-1 medications for weight loss?+
Molina Medicaid plans follow each state's Medicaid drug list, so GLP-1 weight-loss coverage depends on your state. We have not yet reviewed a Molina coverage document. GLP-1 coverage at Molina varies plan by plan. For Wegovy and Zepbound (weight-loss indications), expect prior authorization at minimum, with formal documentation of BMI and previous lifestyle interventions. For Ozempic and Mounjaro (type 2 diabetes), coverage is generally easier when prescribed for diabetes.
Does Molina Healthcare require a prior authorization for Wegovy or Zepbound?+
Yes, prior authorization (PA) is the norm for weight-loss GLP-1s across Molina plans. A PA typically requires documented BMI ≥30 (or ≥27 with a comorbidity), prior attempts at structured weight loss, and sometimes step-therapy through cheaper alternatives. Your prescriber's office files the PA.
How do I check if my specific Molina plan covers a drug?+
Three steps: (1) Log into your Molina member portal and search the drug formulary by name. (2) Call the member services number on your insurance card. (3) Ask your prescriber to submit a benefits inquiry. Plan designs differ widely within Molina Healthcare — what's covered for one member may not be covered for another.
What if Molina denies my GLP-1 prior authorization?+
Three options: (1) Appeal — most plans grant an appeal that adds physician peer-to-peer review; your prescriber can request this. (2) Switch indication if clinically appropriate (e.g., if you have prediabetes and BMI ≥30, your physician may have different coverage paths). (3) Use manufacturer direct-pay (NovoCare, LillyDirect) which doesn't depend on insurance approval. Federal program coverage policies follow CMS rules and have less plan-by-plan variability — appeals are still available.
Are compounded GLP-1s covered by Molina?+
Generally no. Most insurance plans, including Molina, do not cover compounded semaglutide or tirzepatide regardless of pharmacy. As of 2026, the FDA is winding down large-scale compounding, so coverage questions are increasingly moot — most patients are transitioning to branded GLP-1s or manufacturer direct-pay programs.